Amneal Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +50.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 52.8x | Better than 9% |
| Forward P/E | 38.1x | Better than 11% |
| Price / Sales | 2.3x | Better than 52% |
| P/E vs own 5-yr range | 69th pctl | Better than 39% |
Growth C+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 10.9% | Better than 67% |
| Net income CAGR (3Y) | -18.4% | Better than 19% |
| Free cash flow CAGR (3Y) | 5.2% | Better than 46% |
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 36.9% | Better than 43% |
| Operating margin | 13.2% | Better than 60% |
| Net margin | 2.4% | Better than 34% |
| Return on equity | -52.8% | Better than 9% |
| Return on invested capital | 2.4% | Better than 35% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 17.9% | Better than 95% |
| 6-month return | 70.0% | Better than 98% |
| 12-month return (ex latest month) | 70.5% | Better than 90% |
| Distance below 52-week high | 4.5% | Better than 95% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.2x | Better than 60% |
| Debt to assets | 73.1% | Better than 5% |
| Interest coverage | 1.6x | Better than 33% |
| Free cash flow / net income | 313.1% | Better than 86% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 15.5% | Better than 24% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 21.39
- Open
- 21.26
- Day range
- 21.07 - 21.71
- Avg price
- 21.22
- Volume
- 1.67M
- Turnover
- 35.50M
- Turnover ratei
- 0.88%
- Volume ratioi
- 0.89
- Amplitudei
- 2.99%
- 52-week rangei
- 11.71 - 22.13
Valuation
- P/Ei
- 96.00
- P/E (TTM)i
- 52.80
- P/Bi
- 13.85
- EPSi
- 0.22
- Book value / shi
- 1.53
- Net profit
- 76.65M
- Net assets
- 531.33M
Share structure
- Market cap
- 7.36B
- Float capi
- 4.03B
- Shares out
- 348.41M
- Float sharesi
- 190.89M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
4.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-5.52M net over the window
Short interest
- Shares short
- 11.39M
- % of floati
- 3.57%
- Days to coveri
- 2.79
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Amneal Pharmaceuticals (AMRX)?
Amneal Pharmaceuticals last traded at 21.12. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Amneal Pharmaceuticals's market cap?
About 7.36B.
What is the P/E ratio of Amneal Pharmaceuticals?
The trailing twelve-month P/E is 52.80, below its own 5-year average of 122.82 — toward the top of its historical range (68.82% percentile). See the Valuation tab for the full history.
Does Amneal Pharmaceuticals pay a dividend?
Amneal Pharmaceuticals does not currently pay a regular dividend.
Is Amneal Pharmaceuticals a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 24.40, which implies 15.5% upside from the current price. This is not investment advice.
What is Amneal Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Amneal Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.
Amneal Pharmaceuticals discussion 0 comments